What’s happened 

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 3 Medicines Recall for a specific batch of Flucloxacillin Capsules BP 500mg manufactured by Flamingo Pharma UK Ltd. (Batch number 1600636 expiry 31/08/2028). 

The recall follows the discovery that affected packs contain the patient information leaflet (PIL) for Amoxicillin 500mg Capsules rather than the correct leaflet for Flucloxacillin. 

Healthcare providers are advised to stop supplying the affected batch immediately, quarantine any remaining stock and return it to their supplier using the supplier's approved process. 

Why this matters to members 

Members who supply Flucloxacillin under the POM-S annotation from clinical stocks should check whether they hold any of the affected batch. Any remaining stock should be quarantined and returned to the supplier in line with the recall notice. 

Although the issue relates to the patient information leaflet rather than the medicine itself, the MHRA advises that the affected packs should not be supplied to patients. 

What happens next 

The MHRA has published details of the affected batch numbers together with the actions healthcare providers should take. 

Members are encouraged to review the recall notice and ensure any affected stock is removed from use. 

Links and references 

Class 3 Medicines Recall: Flamingo Pharma UK Ltd, Flucloxacillin Capsules BP 500mg, EL(26)A/32 

• This article was updated on 2 July 2026 to include the affected batch number and expiry date, and to clarify that the recall is relevant to members who supply Flucloxacillin under the POM-S annotation from clinical stocks.